Lancer Orthodontics, Inc. (LANZ)

Lancer Orthodontics, Inc. (LANZ) — VMCI valuation read

Headline read on LANZ: VMCI of 54/100 versus a Healthcare sector median of 50. The 4-point above-median position is what makes Lancer Orthodontics, Inc. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on LANZ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on LANZ: value (LANZ trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.7x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

LANZ rose 2.1% over the trailing 7 days, with a -3.8% read on a 30-day basis.